Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 3
2011 13
2012 30
2013 72
2014 84
2015 80
2016 98
2017 105
2018 113
2019 110
2020 124
2021 141
2022 151
2023 131
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,137 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
Garcia Molina A. Garcia Molina A. Farm Hosp. 2024 Apr 27:S1130-6343(24)00044-8. doi: 10.1016/j.farma.2024.03.008. Online ahead of print. Farm Hosp. 2024. PMID: 38679535 English, Spanish.
AIMS: To establish a cost-effectiveness model comparing asciminib to approved third-generation tyrosine kinase inhibitors (TKIs) (bosutinib and ponatinib) with a focus on achieving TFR. Additionally, the budgetary impact of incorporating asciminib as a therapeutic alternat …
AIMS: To establish a cost-effectiveness model comparing asciminib to approved third-generation tyrosine kinase inhibitors (TKIs) (bosutinib …
Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis.
Krajcsir B, Pócsi M, Fejes Z, Nagy B Jr, Kappelmayer J, Beke Debreceni I. Krajcsir B, et al. Pharmaceutics. 2024 Apr 19;16(4):559. doi: 10.3390/pharmaceutics16040559. Pharmaceutics. 2024. PMID: 38675220 Free PMC article.
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective drugs in the treatment of patients with chronic myeloid leukemia. However, based on clinical studies, ponatinib was associated with the development of thrombotic complications. ...Therapeutic concentrations of pona …
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective drugs in the treatment of patients with chronic myeloid leukemia. However, based on …
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
Marra JD, Galli E, Giammarco S, Metafuni E, Minnella G, Fosso F, Marietti S, Sica S, Sorà F, Chiusolo P. Marra JD, et al. Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217. Online ahead of print. Eur J Haematol. 2024. PMID: 38644613
We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. …
We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who und …
Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case Report.
Nomura T, Hata A. Nomura T, et al. Ann Vasc Dis. 2024 Mar 25;17(1):51-54. doi: 10.3400/avd.cr.23-00059. Epub 2023 Nov 28. Ann Vasc Dis. 2024. PMID: 38628933 Free PMC article.
A 72-year-old woman with chronic myeloid leukemia with T315I mutation in breakpoint cluster region-abelson (BCR-ABL) was treated with ponatinib. During the course of her treatment, chronic limb-threatening ischemia developed in both lower extremities, and the left lower ex …
A 72-year-old woman with chronic myeloid leukemia with T315I mutation in breakpoint cluster region-abelson (BCR-ABL) was treated with pon …
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts.
Holzmayer SJ, Kauer J, Mauermann J, Roider T, Märklin M. Holzmayer SJ, et al. Cancers (Basel). 2024 Mar 26;16(7):1288. doi: 10.3390/cancers16071288. Cancers (Basel). 2024. PMID: 38610966 Free PMC article.
NK cell activation, proliferation, degranulation, cytokine release and tumor cell lysis were analyzed. In contrast to ATP site inhibitors such as dasatinib and ponatinib, the novel first-in-class selective allosteric ABL myristoyl pocket (STAMP) inhibitor asciminib did not …
NK cell activation, proliferation, degranulation, cytokine release and tumor cell lysis were analyzed. In contrast to ATP site inhibitors su …
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Short NJ, et al. Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329. Online ahead of print. Am J Hematol. 2024. PMID: 38607091 No abstract available.
Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review.
Wang L, Qiu Q, Yang D, Cao C, Lu Y, Zeng Y, Jiang W, Shen Y, Ye Y. Wang L, et al. Front Pharmacol. 2024 Mar 22;15:1173240. doi: 10.3389/fphar.2024.1173240. eCollection 2024. Front Pharmacol. 2024. PMID: 38584599 Free PMC article. Review.
These trials employed diverse drug combinations, incorporating agents such as ponatinib, bicalutamide, dalotuzumab, MK-2206, MK-0752, and taxanes. ...
These trials employed diverse drug combinations, incorporating agents such as ponatinib, bicalutamide, dalotuzumab, MK-2206, MK-0752, …
Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells.
Tezcanli Kaymaz B, Gumus N, Celik B, Alcitepe İ, Biray Avci C, Aktan C. Tezcanli Kaymaz B, et al. J Interferon Cytokine Res. 2024 Apr;44(4):178-189. doi: 10.1089/jir.2023.0170. J Interferon Cytokine Res. 2024. PMID: 38579140
As treatment with the STAT5 inhibitor pimozide in combination with ponatinib resulted in an efficient and synergistic therapeutic approach in TKI-resistant CML cells, this study focused on identifying the underlying amplification of ponatinib response mechanisms by …
As treatment with the STAT5 inhibitor pimozide in combination with ponatinib resulted in an efficient and synergistic therapeutic app …
Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by SCORE2 algorithm.
Szczepanek E, Marczyk B, Chukwu O, Chlopicki S, Sacha T. Szczepanek E, et al. Pol Arch Intern Med. 2024 Apr 3:16719. doi: 10.20452/pamw.16719. Online ahead of print. Pol Arch Intern Med. 2024. PMID: 38572907 Free article.
PATIENTS AND METHODS: Forty-eight patients diagnosed with chronic phase CML treated with TKIs, such as imatinib, bosutinib, nilotinib, ponatinib, and asciminib were included. Endothelial function was assessed in the brachial artery and microcirculation based on flow-mediat …
PATIENTS AND METHODS: Forty-eight patients diagnosed with chronic phase CML treated with TKIs, such as imatinib, bosutinib, nilotinib, po …
1,137 results